OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced the company’s dengue vaccine, QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was ...

An international team of researchers has demonstrated that the tetravalent dengue vaccine known as Qdenga provided significant protection against the disease under real-world conditions, during the ...

Takeda's dengue vaccine has so far picked up approvals in Indonesia, Brazil, Thailand, Argentina, Europe and the U.K. (Takeda) With a new manufacturing partnership in India, Takeda has added new ...

Mosquito-Borne Diseases: Hopes are rising for a dengue vaccine called Qdenga. According to reports, this vaccine could be launched in India by 2026. Let's explain it. When will the Qdenga vaccine ...

Annapurna Das, General Manager, Takeda Biopharmaceuticals India Pvt Ltd, with 20 years of experience in the pharmaceutical and biotechnology industry across India and Southeast Asia, spoke to ETPharma ...

India is all set to take a major step in public health with the approval of its first dengue vaccine, Qdenga (TAK-003), developed by Takeda Pharmaceutical Company and manufactured locally with ...

India’s long wait for a dengue vaccine may finally be coming to an end. Takeda’s tetravalent dengue vaccine, TAK-003 (called ‘Qdenga’), recently received clearance from the Subject Expert Committee ...

“Dengue can affect anyone living in or traveling to endemic areas - regardless of age, health and socio-economic circumstances,” said Gary Dubin, president of Takeda’s Vaccine Business Unit.

An international team of researchers has demonstrated that the tetravalent dengue vaccine Qdenga provides significant protection against the disease under real-world conditions, during the large 2024 ...